MEZOFY Drug Patent Profile
✉ Email this page to a colleague
When do Mezofy patents expire, and when can generic versions of Mezofy launch?
Mezofy is a drug marketed by Cmg Pharm Co Ltd and is included in one NDA. There is one patent protecting this drug.
The generic ingredient in MEZOFY is aripiprazole. There is one drug master file entry for this compound. Fifty suppliers are listed for this compound. Additional details are available on the aripiprazole profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Mezofy
A generic version of MEZOFY was approved as aripiprazole by ALEMBIC on April 28th, 2015.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for MEZOFY?
- What are the global sales for MEZOFY?
- What is Average Wholesale Price for MEZOFY?
Summary for MEZOFY
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Patent Applications: | 6,225 |
| DailyMed Link: | MEZOFY at DailyMed |
US Patents and Regulatory Information for MEZOFY
MEZOFY is protected by one US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cmg Pharm Co Ltd | MEZOFY | aripiprazole | FILM;ORAL | 211448-001 | Apr 15, 2025 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Cmg Pharm Co Ltd | MEZOFY | aripiprazole | FILM;ORAL | 211448-002 | Apr 15, 2025 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Cmg Pharm Co Ltd | MEZOFY | aripiprazole | FILM;ORAL | 211448-003 | Apr 15, 2025 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for MEZOFY
See the table below for patents covering MEZOFY around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 2883540 | PRÉPARATION DE FILM BUCCAL Ă€ DISSOLUTION RAPIDE COMPRENANT DE L'ARIPIPRAZOLE (FAST-DISSOLVING ORAL FILM PREPARATION COMPRISING ARIPIPRAZOLE) | ⤷ Start Trial |
| Spain | 2636792 | ⤷ Start Trial | |
| South Korea | 101571670 | ⤷ Start Trial | |
| South Korea | 20140021141 | FORMULATION FOR ORODISPERSIBLE FILM COMPRISING ARIPIRAZOLE | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2014025206 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for MEZOFY
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1675573 | C300669 | Netherlands | ⤷ Start Trial | PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115 |
| 1675573 | 92427 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: ARIPIPRAZOLE |
| 0367141 | SPC/GB04/039 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: ARIPIPRAZOLE OR A SALT THEREOF; REGISTERED: UK EU/1/04/276/001 20040604; UK EU/1/04/276/002 20040604; UK EU/1/04/276/003 20040604; UK EU/1/04/276/004 20040604; UK EU/1/04/276/005 20040604; UK EU/1/04/276/006 20040604; UK EU/1/04/276/007 20040604; UK EU/1/04/276/008 20040604; UK EU/1/04/276/009 20040604; UK EU/1/04/276/010 20040604; UK EU/1/04/276/011 20040604; UK EU/1/04/276/012 20040604; UK EU/1/04/276/013 20040604; UK EU/1/04/276/014 20040604; UK EU/1/04/276/015 20040604; UK EU/1/04/276/016 20040604; UK EU/1/04/276/017 20040604; UK EU/1/04/276/018 20040604; UK EU/1/04/276/019 20040604; UK EU/1/04/276/020 20040604 |
| 1675573 | 300669 | Netherlands | ⤷ Start Trial | PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115 |
| 1675573 | 2014C/029 | Belgium | ⤷ Start Trial | PRODUCT NAME: ARIPIPRAZOLE; AUTHORISATION NUMBER AND DATE: EU/1/13/882 20131119 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch